Literature DB >> 29321207

Aberrantly high expression of the CUB and zona pellucida-like domain-containing protein 1 (CUZD1) in mammary epithelium leads to breast tumorigenesis.

Janelle Mapes1, Lavanya Anandan1, Quanxi Li2, Alison Neff1, Charles V Clevenger3, Indrani C Bagchi2, Milan K Bagchi4.   

Abstract

The peptide hormone prolactin (PRL) and certain members of the epidermal growth factor (EGF) family play central roles in mammary gland development and physiology, and their dysregulation has been implicated in mammary tumorigenesis. Our recent studies have revealed that the CUB and zona pellucida-like domain-containing protein 1 (CUZD1) is a critical factor for PRL-mediated activation of the transcription factor STAT5 in mouse mammary epithelium. Of note, CUZD1 controls production of a specific subset of the EGF family growth factors and consequent activation of their receptors. Here, we found that consistent with this finding, CUZD1 overexpression in non-transformed mammary epithelial HC11 cells increases their proliferation and induces tumorigenic characteristics in these cells. When introduced orthotopically in mouse mammary glands, these cells formed adenocarcinomas, exhibiting elevated levels of STAT5 phosphorylation and activation of the EGF signaling pathway. Selective blockade of STAT5 phosphorylation by pimozide, a small-molecule inhibitor, markedly reduced the production of the EGF family growth factors and inhibited PRL-induced tumor cell proliferation in vitro Pimozide administration to mice also suppressed CUZD1-driven mammary tumorigenesis in vivo Analysis of human MCF7 breast cancer cells indicated that CUZD1 controls the production of the same subset of EGF family members in these cells as in the mouse. Moreover, pimozide treatment reduced the proliferation of these cancer cells. Collectively, these findings indicate that overexpression of CUZD1, a regulator of growth factor pathways controlled by PRL and STAT5, promotes mammary tumorigenesis. Blockade of the STAT5 signaling pathway downstream of CUZD1 may offer a therapeutic strategy for managing these breast tumors.
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  STAT transcription factor; breast cancer; epidermal growth factor receptor (EGFR); prolactin; tumor cell biology

Mesh:

Substances:

Year:  2018        PMID: 29321207      PMCID: PMC5827451          DOI: 10.1074/jbc.RA117.000162

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  88 in total

1.  Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation.

Authors:  Yongzhi Cui; Greg Riedlinger; Keiko Miyoshi; Wei Tang; Cuiling Li; Chu-Xia Deng; Gertraud W Robinson; Lothar Hennighausen
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

2.  Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies.

Authors:  Polychronis Pavlidis; Lars Komorowski; Bianca Teegen; Christos Liaskos; Andreas L Koutsoumpas; Daniel S Smyk; Carlo Perricone; Maria G Mytilinaiou; Winfried Stocker; Alastair Forbes; Dimitrios P Bogdanos
Journal:  Clin Chem Lab Med       Date:  2016-02       Impact factor: 3.694

3.  The genes induced by signal transducer and activators of transcription (STAT)3 and STAT5 in mammary epithelial cells define the roles of these STATs in mammary development.

Authors:  Richard W E Clarkson; Marion P Boland; Ekaterini A Kritikou; Jennifer M Lee; Tom C Freeman; Paul G Tiffen; Christine J Watson
Journal:  Mol Endocrinol       Date:  2005-11-17

4.  Cloning and uterus/oviduct-specific expression of a novel estrogen-regulated gene (ERG1)

Authors:  D Chen; X Xu; L J Zhu; M Angervo; Q Li; M K Bagchi; I C Bagchi
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

Review 5.  The role of prolactin in mammary carcinoma.

Authors:  Charles V Clevenger; Priscilla A Furth; Susan E Hankinson; Linda A Schuler
Journal:  Endocr Rev       Date:  2003-02       Impact factor: 19.871

6.  Stat5a is mandatory for adult mammary gland development and lactogenesis.

Authors:  X Liu; G W Robinson; K U Wagner; L Garrett; A Wynshaw-Boris; L Hennighausen
Journal:  Genes Dev       Date:  1997-01-15       Impact factor: 11.361

7.  Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.

Authors:  C T C Leong; C K Ong; S K Tay; H Huynh
Journal:  Oncogene       Date:  2006-07-24       Impact factor: 9.867

Review 8.  Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.

Authors:  G Atalay; F Cardoso; A Awada; M J Piccart
Journal:  Ann Oncol       Date:  2003-09       Impact factor: 32.976

Review 9.  Mammary gland growth factors: roles in normal development and in cancer.

Authors:  Nancy E Hynes; Christine J Watson
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-16       Impact factor: 10.005

10.  Genome-wide analyses reveal the extent of opportunistic STAT5 binding that does not yield transcriptional activation of neighboring genes.

Authors:  Bing-Mei Zhu; Keunsoo Kang; Ji Hoon Yu; Weiping Chen; Harold E Smith; Daeyoup Lee; Hong-Wei Sun; Lai Wei; Lothar Hennighausen
Journal:  Nucleic Acids Res       Date:  2012-02-08       Impact factor: 16.971

View more
  5 in total

1.  The developmentally regulated fetal enterocyte gene, ZP4, mediates anti-inflammation by the symbiotic bacterial surface factor polysaccharide A on Bacteroides fragilis.

Authors:  Frida Gorreja; Stephen Ta Rush; Dennis L Kasper; Di Meng; W Allan Walker
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-07-17       Impact factor: 4.052

2.  Variants in the pancreatic CUB and zona pellucida-like domains 1 (CUZD1) gene in early-onset chronic pancreatitis - A possible new susceptibility gene.

Authors:  Agnieszka Magdalena Rygiel; Lara Sophie Unger; Franziska Lena Sörgel; Emmanuelle Masson; Ryotaro Matsumoto; Maren Ewers; Jian-Min Chen; Peter Bugert; Louis Buscail; Tomasz Gambin; Grzegorz Oracz; Maria Winiewska-Szajewska; Agnieszka Mianowska; Jarosław Poznanski; Joanna Kosińska; Piotr Stawinski; Rafał Płoski; Dorota Koziel; Stanisław Gluszek; Helmut Laumen; Fredrik Lindgren; J Matthias Löhr; Anna Orekhova; Vinciane Rebours; Jonas Rosendahl; Andrea Párniczky; Péter Hegyi; Akira Sasaki; Fumiya Kataoka; Yu Tanaka; Shin Hamada; Miklós Sahin-Tóth; Eszter Hegyi; Claude Férec; Atsushi Masamune; Heiko Witt
Journal:  Pancreatology       Date:  2022-05-01       Impact factor: 3.977

3.  Immunologic Profiling of the Atlantic Salmon Gill by Single Nuclei Transcriptomics.

Authors:  Alexander C West; Yasutaka Mizoro; Shona H Wood; Louise M Ince; Marianne Iversen; Even H Jørgensen; Torfinn Nome; Simen Rød Sandve; Samuel A M Martin; Andrew S I Loudon; David G Hazlerigg
Journal:  Front Immunol       Date:  2021-05-04       Impact factor: 7.561

Review 4.  Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy.

Authors:  Vikram Shaw; Suyash Srivastava; Sanjay K Srivastava
Journal:  Semin Cancer Biol       Date:  2019-10-13       Impact factor: 15.707

5.  STAT5a Confers Doxorubicin Resistance to Breast Cancer by Regulating ABCB1.

Authors:  Zhaoqing Li; Cong Chen; Lini Chen; Dengdi Hu; Xiqian Yang; Wenying Zhuo; Yongxia Chen; Jingjing Yang; Yulu Zhou; Misha Mao; Xun Zhang; Ling Xu; Siwei Ju; Jun Shen; Qinchuan Wang; Minjun Dong; Shuduo Xie; Qun Wei; Yunlu Jia; Jichun Zhou; Linbo Wang
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.